1. Home
  2. IMSR vs GERN Comparison

IMSR vs GERN Comparison

Compare IMSR & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Terrestrial Energy Inc.

IMSR

Terrestrial Energy Inc.

HOLD

Current Price

$6.73

Market Cap

901.5M

Sector

N/A

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.32

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMSR
GERN
Founded
2013
1990
Country
United States
United States
Employees
74
258
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
901.5M
808.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IMSR
GERN
Price
$6.73
$1.32
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$2.17
AVG Volume (30 Days)
3.0M
13.0M
Earning Date
05-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$26.91
Revenue Next Year
N/A
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.33
$1.04
52 Week High
$16.38
$2.01

Technical Indicators

Market Signals
Indicator
IMSR
GERN
Relative Strength Index (RSI) 40.77 50.84
Support Level $5.82 $1.23
Resistance Level $6.85 $1.30
Average True Range (ATR) 0.65 0.08
MACD -0.14 0.03
Stochastic Oscillator 9.56 52.56

Price Performance

Historical Comparison
IMSR
GERN

About IMSR Terrestrial Energy Inc.

Terrestrial Energy Inc is a technology company engaged in the development and commercialization of nuclear power plants. The company is focused on its proprietary Integral Molten Salt Reactor (IMSR) technology, a Generation IV reactor design intended to produce reliable, emission-free energy in the form of electricity and high-temperature heat for industrial applications. Its activities mainly involve advancing the design, licensing, and deployment of IMSR plants for commercial energy generation.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: